Breaks Categories: Stock Spotlights

ThursdayApr 06, 2017 12:46 pm

NetworkNewsBreaks – Nova LifeStyle, Inc. (NASDAQ: NVFY) Opens New Facility in Hong Kong Following Record-Breaking Monthly Members Sign-ups; Shares Soar

Nova LifeStyle (NASDAQ: NVFY) shares surged 48% on the company’s report of a record amount of new paying customers and student members signing up for its online and classroom-based Blockchain programs during the month of March. The company reported more than 2,000 new sign-ups in March, doubling its enrollment from February sign-ups. Additionally, the company recently opened its Digital Assets Cultural Hall in Kwun Tong, Hong Kong which is designed to accommodate customers seeking to participate in Nova’s Blockchain training program. “We continue to see strong customer and student member sign-ups for our lecture-based programs as well as on our…

Continue Reading

WednesdayApr 05, 2017 1:45 pm

NetworkNewsBreaks – National Waste Management Holdings, Inc. (NWMH) Reducing Environmental Impact of Construction and Demolition Rubble

According to the Environmental Protection Agency (http://nnw.fm/WeFZ4), over 500 million tons of construction and demolition (C&D) debris were generated in 2014. National Waste Management Holdings, Inc. (OTC: NWMH) aims to reduce the impact these debris have on the environment while growing in vertical markets. “The company is focused on operating according to an eco-friendly business model that has been put in place to combat unnecessary waste in Florida and New York. To pursue its mission of being environmentally conscience with a focus on sustainability, NWMH is committed to inspecting all loads and sorting all the materials that arrive in its…

Continue Reading

TuesdayApr 04, 2017 3:49 pm

NetworkNewsBreaks – CytoDyn Inc. (CYDY) Advances PRO 140 to Provide a Better Quality of Life for HIV Patients

More than 34 million people have died from HIV since it was first discovered in 1981, according to Healthline (http://nnw.fm/i9ptS). Although there is no known cure for the disease, CytoDyn Inc. (OTCQB: CYDY) is advancing its drug candidate toward providing a better life for HIV patients. “PRO 140 is currently one of the most advanced experimental monoclonal antibodies for HIV treatment, and CYDY believes that it will be beneficial to patients with complicating issues, such as those with single or multi-drug resistant viruses or those who have difficulty sticking to a daily drug regimen, as well as those who can’t…

Continue Reading

TuesdayApr 04, 2017 11:19 am

NetworkNewsBreaks – Evoke Pharma (NASDAQ: EVOK) Moves Forward with Comparative Exposure PK Trial for Gimoti NDA Following Type A Meeting with FDA

Evoke Pharma (NASDAQ: EVOK) shares rallied as much as 11% this morning after the company provided details of its positive Type A meeting with the U.S. Food and Drug Administration (FDA). Evoke met with the FDA to finalize the design of the pivotal comparative exposure pharmacokinetic (PK) trial and to reach agreement on additional aspects of the Chemistry, Manufacturing & Controls (CMC) section of the New Drug Application (NDA) for Gimoti™ for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adult women. The pivotal comparative exposure PK trial will be conducted in healthy volunteers to demonstrate…

Continue Reading

TuesdayApr 04, 2017 11:17 am

NetworkNewsBreaks – Diffusion Pharmaceuticals, Inc. (NASDAQ: DFFN) Receives Patent for TSC in Five Hypoxia-Related Indications; Shares Rally

Shares of Diffusion Pharmaceuticals (NASDAQ: DFFN) surged as much as 23% this morning after the company announced that the U.S. Patent and Trademark Office (USPTO) has issued a key patent for the company’s lead drug candidate, trans sodium crocetinate (TSC). Diffusion’s existing patents currently include the use of TSC in oncology, stroke and neurodegenerative disease indications. The new patent increases coverage of the therapeutic use of TSC and other related compounds to five hypoxia-related conditions including congestive heart failure, chronic renal failure, acute lung injury, chronic obstructive pulmonary disease, and respiratory distress syndrome. “Receiving the patent from the USPTO validates…

Continue Reading

MondayApr 03, 2017 1:41 pm

NetworkNewsBreaks – Cancer Genetics, Inc. (NASDAQ: CGIX) Enters Strategic Partnership with Mendel.ai to Employ Artificial Intelligence in Precision Medicine

Cancer Genetics (NASDAQ: CGIX) (“CGI”) has entered into a strategic partnership with Mendel Health, an artificial intelligence company focused on using the Mendel.ai deep-learning engine to accelerate and constantly update clinical trial matching for patients. The companies will be collaborating to integrate Mendel.ai capabilities for clinicians, oncologists and pathologists, as well as cancer centers and hospitals with CGI’s disease-focused reports and testing results. The companies anticipate that initial, early-access partners will be using the system during the second quarter of 2017 with a more extensive rollout through the third and fourth quarters of this year. “Artificial intelligence has advanced and…

Continue Reading

MondayApr 03, 2017 12:22 pm

NetworkNewsBreaks – Interpace Diagnostics (NASDAQ: IDXG) Receives European Patent Approval For Core Technology of its ThyraMIR® microRNA Classifier

Interpace Diagnostics (NASDAQ: IDXG) shares are up 7% after the company said this morning that the European Patent Office granted it a patent for use of microRNAs for distinguishing benign from malignant thyroid neoplasms. This patent covers the underlying technology of the company's ThyraMIR® microRNA Classifier. Interpace intends to validate and enforce this Intellectual Property in select European countries going forward. "We are pleased to announce the approval of this patent by the European Patent Office as it provides a basis for introducing our first product to the European market as part of our international expansion plan. Importantly, this patent…

Continue Reading

FridayMar 31, 2017 12:56 pm

NetworkNewsBreaks – SeeThruEquity Issues Coverage Update, Raises PT to $1.50 on Generation Next Franchise Brands, Inc. (VEND)

SeeThruEquity recently issued an update on Generation Next Franchise Brands (OTCQB: VEND) and raised the price target on shares of the company’s stock to $1.50. The company recently entered into the frozen yogurt market through its three newly-formed subsidiaries: Reis and Irvy's Inc., 19 Degrees, Inc., and Generation Next Vending Robots, Inc. SeeThruEquity noted that the company appears to be gaining traction in the market and attributes the positive positioning to the company’s backlog of deferred revenue related to Froyo Robot bookings, franchise agreements, and an added revenue stream from royalties. The analyst also cited the company’s strengthened intellectual property…

Continue Reading

FridayMar 31, 2017 12:47 pm

NetworkNewsBreaks – ROTH Capital Partners To Host 4th Annual ROTH China Solar Tour in Conjunction with SNEC Power Expo in Shanghai

ROTH Capital Partners is hosting its 4th Annual China Solar Tour in Shanghai on April 18-21, 2017. The invitation-only event will be held in conjunction with the SNEC Power Expo, one of the largest annual solar conferences in the world. The event will be hosted by ROTH’s Philip Shen, senior research analyst, Cleantech, and will provide an opportunity for solar power industry executives, policymakers and key institutional investors to meet and exchange ideas about issues and trends in the solar and cleantech industry. “Innovation and growth continue to fuel the global solar industry, and China is a key centerpiece of…

Continue Reading

FridayMar 31, 2017 11:16 am

NetworkNewsBreaks – BioDelivery Sciences (NASDAQ: BDSI) Shares Higher on New Patents Protecting BELBUCA®, BUNAVAIL® and ONSOLIS®

BioDelivery Sciences (NASDAQ: BDSI) shares are up 7% after the company this morning said that it has received two new patents further strengthening BDSI's overall intellectual property position. The new patents protect all three of its FDA-approved products: BELBUCA® buccal film, BUNAVAIL® buccal film, and ONSOLIS®. One patent covers the composition of the BioErodible MucoAdhesive (BEMA®) drug delivery technology, which provides additional patent coverage for BELBUCA and BUNAVAIL to July 2027 and will be listed in the Orange Book. The second patent, also to be listed in the Orange Book, extends protection on ONSOLIS from January 2020 to July 2027.…

Continue Reading